Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in vitro diagnostics company dedicated to providing solutions to the global challenge of drug resistant organisms and hospital acquired infections. We are focused on developing and commercializing innovative instrumentation for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The Company’s revolutionary ID/AST system utilizes a proprietary culture-free process, with both genomic and phenotypic detection technologies, that significantly decreases time to result while achieving high sensitivity and specificity.
Location: United States, Arizona, Tucson
Employees: 201-500
Phone: 520.365.3100
Founded date: 1987
Investors 1
| Date | Name | Website |
| - | CARB-X | carb-x.org |
Mentions in press and media 8
| Date | Title | Description |
| 15.11.2023 | Cytovale Snags $84M To Commercialize Early Sepsis Detection Test | Sepsis kills more than 11 million people worldwide each year and contributes to 20% of all global deaths. The disease is also a leading cause of death in U.S. hospitals, and a septic patient’s risk of death increases by 8% each hour they go... |
| 23.09.2021 | Accelerate Diagnostics : Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock | TUCSON, Ariz., Sept. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.50% Convertible Senior Notes... |
| 23.09.2021 | Accelerate Diagnostics : Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock (Form 8-K) | Accelerate Diagnostics Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock TUCSON, Ariz., September 23, 2021 - Accelerate Diagnostics, Inc. (Nasdaq: ... |
| 03.08.2021 | Accelerate Diagnostics Announces CE Mark and Availability in Europe of Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems | |
| 07.07.2021 | Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States | |
| 09.06.2021 | ACCELERATE DIAGNOSTICS, INC. Accelerate Diagnostics : Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections | Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections Jun 08, 2021 CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global no... |
| 23.02.2021 | Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2020 Financial Results | |
| 24.10.2019 | New diagnostic tools are essential in the battle against antibiotic resistance | A century ago, a severe bacterial infection was often a death sentence. With the advent of penicillin and the antibiotics that followed, such infections became eminently manageable, even routine. Today, though, with the rise of antimicrobia... |